What's Going On With Sangamo Therapeutics Shares Tuesday?
What's Going On With Sangamo Therapeutics Shares Tuesday?
"Fabry is a debilitating disease, for which there is a serious unmet medical need," said Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares are moving higher Tuesday after the company announced the FDA approved an accelerated pathway for ST-920, a potential gene therapy for the treatment of Fabry disease.
醫療保健板塊公司Sangamo Therapeutics, Inc. (納斯達克股票代碼: SGMO) 的股價在週二上漲，因爲該公司宣佈FDA已批准了St-920的加速途徑，這是一種治療法布瑞病潛在的基因療法。
What To Know: The FDA's approval of the accelerated pathway was based on data from the ongoing Phase 1/2 STAAR study. Without an accelerated pathway, the company would have to conduct an additional study. Tuesday's announcement will allow Sangamo to forego the extra study, speeding up the estimated time to potential approval by approximately three years.
需要了解的是：FDA批准加速途徑的依據是來自正在進行的第1/2期STAAR研究的數據。如果沒有加速途徑，公司將不得不進行額外的研究。週二的公告將允許Sangamo跳過額外的研究，將潛在批准時間提前約三年。
The data from the ongoing study showed promising safety and efficacy results and evidence of improved kidney function. These improvements, particularly in estimated glomerular filtration rate (eGFR), an indicator of kidney function, suggest the potential to address the renal complications commonly seen in Fabry disease.
來自進行中研究的數據顯示了有希望的安全性和療效結果，以及改善腎功能的證據。這些改善，特別是估計的腎小球濾過率（eGFR），是腎功能的指標，表明有望解決法布瑞病中常見的腎臟併發症。
"Fabry is a debilitating disease, for which there is a serious unmet medical need," said Sandy Macrae, CEO of Sangamo.
Sangamo的CEO Sandy Macrae表示：「法布瑞病是一種使人痛苦的疾病，存在嚴重的醫療需求。」
"I strongly believe in the potential for ST-920 to alleviate many manifestations of Fabry disease and am delighted to have a clear regulatory pathway that could bring this treatment to patients significantly sooner than originally anticipated".
「我堅信St-920有望緩解法布瑞病的許多表現，我很高興有一個明確的監管途徑，可以使這種治療比最初預期的時間快得多地送達患者。」
Sangamo said it has begun to execute Biologics License Application (BLA) readiness activities and expects to submit a BLA during the second half of 2025.
Sangamo表示已開始執行生物製品許可申請（BLA）準備工作，並預計在2025年下半年提交BLA。
How To Buy Sangamo Therapeutics Stock
如何購買Sangamo Therapeutics股票
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
除了手動到經紀所平台購買股票或者部分股票，您還可以通過購買持有股票的ETF，或者在401(k)中分配資金進入一項該類基金或其他工具的策略來獲得股票的份額。例如，Coinbase屬於金融部門。ETF通常持有許多能跟蹤該部門的流動性和大型公司的股票，使投資者能夠獲得該股票板塊內的趨勢。
For example, in Sangamo Therapeutics's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
例如，在sangamo therapeutics的情況下，它屬於醫療保健板塊。一個etf很可能持有許多流動性強、規模大的公司股票，幫助跟蹤該板塊的動向，讓投資者獲得該細分市場趨勢的曝光。
SGMO Price Action: At the time of writing, Sangamo shares are up 33.7% at $1.21, according to data from Benzinga Pro.
股價走勢：撰寫時，sangamo股票上漲33.7%，報1.21美元，根據Benzinga Pro的數據。
Image: Courtesy of Sangamo Therapeutics.
圖片：由sangamo therapeutics提供。
譯文內容由第三人軟體翻譯。
